COMPANY HISTORY
The Company was incorporated in the State of Nevada, U.S.A., on September 5, 2002.
The Company has been in the exploration or development stage since its formation and has not yet realized any revenues from its planned operations. It is primarily engaged in the development of technology acquired under license for detection of cancer tumors. The prior business plan of mineral exploration has been abandoned.
Xpention Genetics, Inc. is a biotechnology company that was formed to develop both immunological and molecular tests for cancer detection in animals and humans as well as therapeutic vaccines and other treatment methods for both canine and human cancers.
The Company owns Xpention, Inc., a wholly owned subsidiary, which has entered into the Patent and Technology License Agreement with The University of Texas M.D. Anderson Cancer Center which granted Xpention the exclusive rights to patented technology for the detection of cancer based on a tumor marker known as p65 which has been demonstrated to show elevated levels in the blood of canine and human cancer patients.
The Company was incorporated in the State of Nevada, U.S.A., on September 5, 2002.
The Company has been in the exploration or development stage since its formation and has not yet realized any revenues from its planned operations. It is primarily engaged in the development of technology acquired under license for detection of cancer tumors. The prior business plan of mineral exploration has been abandoned.
Xpention Genetics, Inc. is a biotechnology company that was formed to develop both immunological and molecular tests for cancer detection in animals and humans as well as therapeutic vaccines and other treatment methods for both canine and human cancers.
The Company owns Xpention, Inc., a wholly owned subsidiary, which has entered into the Patent and Technology License Agreement with The University of Texas M.D. Anderson Cancer Center which granted Xpention the exclusive rights to patented technology for the detection of cancer based on a tumor marker known as p65 which has been demonstrated to show elevated levels in the blood of canine and human cancer patients.
